U.S. Track and Field Athlete Kevin Castille Accepts Sanction for Anti-Doping Rule Violation

USADA announced today that Kevin Castille, of Baton Rouge, La., an athlete in the sport of track and field, has accepted a four-year suspension for an anti-doping rule violation.

 

Castille, 48, tested positive for 19-norandrosterone (19-NA), the main urinary metabolite of nandrolone (19-nortestosterone) and other 19-norsteroids,

as a result of an in-competition drug test conducted at the USA Track & Field Masters 10K Championship on April 28, 2019, at which Castille finished first. The presence of 19-NA was confirmed in his urine sample using a specialized test that differentiates between anabolic androgenic steroids (AAS), which are produced naturally by the body, and prohibited anabolic agents of external origin. Anabolic agents have powerful performance-enhancing capabilities and can give an athlete an unfair advantage over fellow competitors.

 

All AAS, including 19-NA, are Non-Specified Substances in the class of Anabolic Agents and are prohibited at all times under the USADA Protocol

for Olympic and Paralympic Movement Testing, the United States Olympic and Paralympic Committee National Anti-Doping Policies, and the World Athletics Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List.

 

Castille contested his case through the applicable arbitration process until he elected to sign an acceptance of sanction form three days before

the arbitration hearing in his case was to begin. Castille accepted a four-year period of ineligibility that began on April 28, 2019, the date his positive sample was collected. In addition, Castille has been disqualified from all competitive results obtained on and subsequent to April 28, 2019, including his first place finish at the USA Track & Field Masters 10K Championship and forfeiture of any medals, points and prizes.